These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36170792)

  • 1. Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019).
    Pfaller M; Mendes RE; Streit JM; Carvalhaes CG
    Diagn Microbiol Infect Dis; 2022 Dec; 104(4):115804. PubMed ID: 36170792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17).
    Carvalhaes CG; Sader HS; Flamm RK; Mendes RE
    J Antimicrob Chemother; 2019 Jul; 74(7):1928-1933. PubMed ID: 30932152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014.
    Pfaller MA; Flamm RK; Jones RN; Farrell DJ; Mendes RE
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5393-9. PubMed ID: 27353270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.
    Jones RN; Flamm RK; Castanheira M; Sader HS; Smart JI; Mendes RE
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):184-187. PubMed ID: 28377166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015).
    Pfaller MA; Sader HS; Shortridge D; Castanheira M; Flamm RK; Mendes RE
    J Chemother; 2019 Jul; 31(4):188-194. PubMed ID: 31079589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019).
    Carvalhaes CG; Sader HS; Rhomberg PR; Castanheira M; DeVries S; Mendes RE
    Pediatr Infect Dis J; 2022 Sep; 41(9):731-735. PubMed ID: 35703275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
    Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
    J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
    Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
    Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.
    Sahm DF; Deane J; Bien PA; Locke JB; Zuill DE; Shaw KJ; Bartizal KF
    Diagn Microbiol Infect Dis; 2015 Feb; 81(2):112-8. PubMed ID: 25488274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America.
    Sader HS; Streit JM; Carvalhaes CG; Huband MD; Pfaller MA
    J Glob Antimicrob Resist; 2019 Jun; 17():103-108. PubMed ID: 30458298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of tedizolid and comparator agents against Gram-positive pathogens responsible for bone and joint infections.
    Ract P; Piau-Couapel C; Compain F; Auzou M; Michon J; Cattoir V
    J Med Microbiol; 2017 Oct; 66(10):1374-1378. PubMed ID: 28920854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.
    Biedenbach DJ; Bouchillon SK; Johnson B; Alder J; Sahm DF
    Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):1933-1939. PubMed ID: 27677280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003.
    Sader HS; Fritsche TR; Streit JM; Jones RN
    J Chemother; 2005 Oct; 17(5):477-83. PubMed ID: 16323435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe.
    Bensaci M; Sahm D
    Diagn Microbiol Infect Dis; 2017 Feb; 87(2):133-138. PubMed ID: 27866673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017-2019).
    Carvalhaes CG; Sader HS; Rhomberg PR; Mendes RE
    Int J Infect Dis; 2021 Jun; 107():92-100. PubMed ID: 33857605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.